Elevance Health Sets 2026 EPS Guidance Amid Membership Declines
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 28 2026
0mins
Should l Buy ELV?
Source: seekingalpha
- 2026 EPS Guidance: Elevance Health has set a target for adjusted diluted earnings per share of at least $25.50 for 2026, despite 2025 results including approximately $3.75 per share from favorable nonrecurring items, indicating a cautious approach amidst challenges.
- Medicaid Business Outlook: CEO Gail Boudreaux highlighted that the Medicaid segment is expected to experience an operating margin of approximately negative 1.75% in 2026, reflecting a focus on long-term sustainability with ongoing rate adjustments and program design changes.
- Medicare Membership Decline: The company anticipates a decline in Medicare Advantage membership in the high teens percentage range for 2026, a strategic move aimed at improving margins, although this may exert short-term pressure on revenues.
- Financial Performance Review: Elevance reported adjusted diluted EPS of $3.33 for Q4 and operating revenue of $49.3 billion for the full year, marking a 10% year-over-year increase, demonstrating robust financial performance under challenging market conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELV
Wall Street analysts forecast ELV stock price to rise
15 Analyst Rating
11 Buy
4 Hold
0 Sell
Moderate Buy
Current: 298.500
Low
332.00
Averages
389.07
High
425.00
Current: 298.500
Low
332.00
Averages
389.07
High
425.00
About ELV
Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to its Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program (FEP) members. The Health Benefits segment also offers health products on a full-risk basis. The CarelonRx segment includes its pharmacy services business. CarelonRx markets and offers pharmacy services to its affiliated health plan customers, as well as to external customers outside of the health plans. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services by offering an array of healthcare-related services and capabilities to internal and external customers through its Carelon Health and Carelon Insights businesses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's GLP-1 Pill Approval Marks New Weight Loss Market Entry
- Regulatory Milestone: The FDA's approval of Eli Lilly's GLP-1 pill, Foundayo, represents a significant advancement for the company in the weight-loss medication market, setting the stage for competition with Novo Nordisk's Wegovy and altering market dynamics.
- Pricing Strategy: Foundayo is priced at $25 per month with insurance or between $149 and $349 out-of-pocket, aiming to attract a broader patient base, particularly appealing to seniors, thereby expanding the market for weight-loss drugs.
- Global Market Expansion: Lilly plans to seek approval for Foundayo in over 40 countries within the next year, leveraging its small molecule nature to enable global production and distribution without cold-chain constraints, enhancing its competitive edge.
- Sales Projections: Analysts estimate Foundayo's sales could reach $14.79 billion by 2030, although lower than Zepbound's $24.68 billion, it still indicates strong market potential and is seen as a key factor for Eli Lilly's stock recovery.
See More
Survey Reveals Rising Uninsured Rate Among ACA Marketplace Participants
- Rising Uninsured Rates: A survey by the Kaiser Family Foundation reveals that nearly 10% of Americans who had health coverage through ACA marketplace plans in 2025 are uninsured in 2026, highlighting the significant impact of expired subsidies.
- Premium Increases: Among those who renewed their plans, 80% reported that their premiums, deductibles, or coinsurance are higher than last year, with about half indicating the increases are 'a lot higher,' which could exacerbate financial strain on households.
- Concerns Over Medical Costs: The survey indicates that nearly 75% of respondents are worried about affording costs for emergency care or hospitalizations, reflecting heightened anxiety over medical expenses that may influence their healthcare decisions.
- Trends in Plan Switching: Of the 69% of respondents who still have marketplace coverage, approximately 39% retained the same plan as last year while 28% switched, with 71% citing cost as a major factor, indicating increasing price sensitivity in the marketplace.
See More
Elevance Health Under Investigation for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating Elevance Health for potential securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- CMS Sanction Notice: On March 2, 2026, Elevance disclosed that CMS intends to impose intermediate sanctions, suspending enrollment of Medicare beneficiaries in its Medicare Advantage-Prescription Drug plans, which is expected to significantly impact the company's operations.
- Stock Price Decline: Following the sanction news, Elevance's stock price fell by $25.93, or 8.1%, closing at $294.07 per share, reflecting market concerns regarding the company's compliance issues.
- Compliance Risks: CMS indicated that the sanctions relate to Elevance's alleged noncompliance with Medicare Advantage risk adjustment data submission requirements prior to April 3, 2023, and failure to address these issues satisfactorily could lead to more severe consequences.
See More
Elevance Health Under Investigation for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating claims on behalf of Elevance Health investors regarding potential securities fraud or unlawful business practices by the company and its executives, highlighting serious concerns about corporate governance.
- Regulatory Sanction Notice: On March 2, 2026, Elevance disclosed that CMS intends to impose intermediate sanctions suspending enrollment of Medicare beneficiaries into its MA-PD plans, indicating significant compliance issues within the company.
- Stock Price Decline: Following the sanction news, Elevance's stock price fell by $25.93, or 8.1%, closing at $294.07 per share on March 2, 2026, reflecting market concerns about the company's future outlook.
- Compliance Risks: CMS indicated that the sanctions relate to Elevance's noncompliance with Medicare Advantage risk adjustment data submission requirements prior to April 3, 2023, which could have profound implications for the company's operations if not resolved by March 31, 2026.
See More
Centene Ranks as the Lowest Performing Stock in the S&P 500 Today: Here's the Reason.
- Stock Performance: Centene's stock has underperformed compared to the broader market this year, reflecting challenges faced by health insurers and managed-care companies.
- Regulatory Concerns: The company is navigating a changing regulatory environment, which has raised concerns among investors.
- Business Update Impact: A recent business update from Centene has heightened investor anxiety regarding the company's future prospects.
- Market Context: The struggles of Centene are indicative of broader issues within the health insurance sector amid evolving regulations.
See More
Insider Buying Activity in SLRC and ELV
- SLRC Insider Purchase: Michael S. Gross acquired 104,819 shares of SLRC on Wednesday at $14.74 each, totaling an investment of $1.55 million, marking his first purchase in the past twelve months, indicating confidence in the company's future.
- Market Price Comparison: On Friday, SLRC shares traded as low as $14.34, which is 2.7% below Gross's purchase price, reflecting short-term market volatility that may influence investor buying decisions.
- ELV Insider Purchase: Elevance Health's Director Steven H. Collis bought 3,000 shares on Thursday at $289.84 each, totaling $869,520, signaling executive optimism regarding the company's prospects.
- ELV Market Price Dynamics: On Friday, ELV shares traded as low as $281.50, which is 2.9% lower than Collis's purchase price, indicating market reactions that could affect other investors' confidence.
See More
Eli Lilly's GLP-1 Pill Approval Marks New Weight Loss Market Entry
- Regulatory Milestone: The FDA's approval of Eli Lilly's GLP-1 pill, Foundayo, represents a significant advancement for the company in the weight-loss medication market, setting the stage for competition with Novo Nordisk's Wegovy and altering market dynamics.
- Pricing Strategy: Foundayo is priced at $25 per month with insurance or between $149 and $349 out-of-pocket, aiming to attract a broader patient base, particularly appealing to seniors, thereby expanding the market for weight-loss drugs.
- Global Market Expansion: Lilly plans to seek approval for Foundayo in over 40 countries within the next year, leveraging its small molecule nature to enable global production and distribution without cold-chain constraints, enhancing its competitive edge.
- Sales Projections: Analysts estimate Foundayo's sales could reach $14.79 billion by 2030, although lower than Zepbound's $24.68 billion, it still indicates strong market potential and is seen as a key factor for Eli Lilly's stock recovery.
See More
Survey Reveals Rising Uninsured Rate Among ACA Marketplace Participants
- Rising Uninsured Rates: A survey by the Kaiser Family Foundation reveals that nearly 10% of Americans who had health coverage through ACA marketplace plans in 2025 are uninsured in 2026, highlighting the significant impact of expired subsidies.
- Premium Increases: Among those who renewed their plans, 80% reported that their premiums, deductibles, or coinsurance are higher than last year, with about half indicating the increases are 'a lot higher,' which could exacerbate financial strain on households.
- Concerns Over Medical Costs: The survey indicates that nearly 75% of respondents are worried about affording costs for emergency care or hospitalizations, reflecting heightened anxiety over medical expenses that may influence their healthcare decisions.
- Trends in Plan Switching: Of the 69% of respondents who still have marketplace coverage, approximately 39% retained the same plan as last year while 28% switched, with 71% citing cost as a major factor, indicating increasing price sensitivity in the marketplace.
See More
Elevance Health Under Investigation for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating Elevance Health for potential securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- CMS Sanction Notice: On March 2, 2026, Elevance disclosed that CMS intends to impose intermediate sanctions, suspending enrollment of Medicare beneficiaries in its Medicare Advantage-Prescription Drug plans, which is expected to significantly impact the company's operations.
- Stock Price Decline: Following the sanction news, Elevance's stock price fell by $25.93, or 8.1%, closing at $294.07 per share, reflecting market concerns regarding the company's compliance issues.
- Compliance Risks: CMS indicated that the sanctions relate to Elevance's alleged noncompliance with Medicare Advantage risk adjustment data submission requirements prior to April 3, 2023, and failure to address these issues satisfactorily could lead to more severe consequences.
See More
Elevance Health Under Investigation for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating claims on behalf of Elevance Health investors regarding potential securities fraud or unlawful business practices by the company and its executives, highlighting serious concerns about corporate governance.
- Regulatory Sanction Notice: On March 2, 2026, Elevance disclosed that CMS intends to impose intermediate sanctions suspending enrollment of Medicare beneficiaries into its MA-PD plans, indicating significant compliance issues within the company.
- Stock Price Decline: Following the sanction news, Elevance's stock price fell by $25.93, or 8.1%, closing at $294.07 per share on March 2, 2026, reflecting market concerns about the company's future outlook.
- Compliance Risks: CMS indicated that the sanctions relate to Elevance's noncompliance with Medicare Advantage risk adjustment data submission requirements prior to April 3, 2023, which could have profound implications for the company's operations if not resolved by March 31, 2026.
See More
Centene Ranks as the Lowest Performing Stock in the S&P 500 Today: Here's the Reason.
- Stock Performance: Centene's stock has underperformed compared to the broader market this year, reflecting challenges faced by health insurers and managed-care companies.
- Regulatory Concerns: The company is navigating a changing regulatory environment, which has raised concerns among investors.
- Business Update Impact: A recent business update from Centene has heightened investor anxiety regarding the company's future prospects.
- Market Context: The struggles of Centene are indicative of broader issues within the health insurance sector amid evolving regulations.
See More
Insider Buying Activity in SLRC and ELV
- SLRC Insider Purchase: Michael S. Gross acquired 104,819 shares of SLRC on Wednesday at $14.74 each, totaling an investment of $1.55 million, marking his first purchase in the past twelve months, indicating confidence in the company's future.
- Market Price Comparison: On Friday, SLRC shares traded as low as $14.34, which is 2.7% below Gross's purchase price, reflecting short-term market volatility that may influence investor buying decisions.
- ELV Insider Purchase: Elevance Health's Director Steven H. Collis bought 3,000 shares on Thursday at $289.84 each, totaling $869,520, signaling executive optimism regarding the company's prospects.
- ELV Market Price Dynamics: On Friday, ELV shares traded as low as $281.50, which is 2.9% lower than Collis's purchase price, indicating market reactions that could affect other investors' confidence.
See More
